 Cystic fibrosis patients who take a type of drug called CFTR modulators have a lower chance of developing a lung infection caused by non-tubricular mycobacteria, NTM, according to a new study published in the Journal of the American Medical Association. The study found that people taking these drugs were less likely to develop NTM than those who did not take them. This article was authored by Emily Iracotta, D. Rebecca Privott and Kenneth N. Olivier.